Caerus Investment Advisors LLC Takes Position in Exelixis, Inc. $EXEL

Caerus Investment Advisors LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 17,638 shares of the biotechnology company’s stock, valued at approximately $773,000.

Several other large investors also recently modified their holdings of the stock. Farallon Capital Management LLC grew its stake in shares of Exelixis by 21.6% in the 3rd quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock valued at $805,412,000 after purchasing an additional 3,466,000 shares during the period. AQR Capital Management LLC grew its stake in shares of Exelixis by 20.7% in the 3rd quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company’s stock valued at $379,190,000 after purchasing an additional 1,575,280 shares during the period. Invesco Ltd. grew its stake in shares of Exelixis by 7.1% in the 3rd quarter. Invesco Ltd. now owns 5,960,525 shares of the biotechnology company’s stock valued at $246,170,000 after purchasing an additional 394,897 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Exelixis by 11.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after purchasing an additional 419,596 shares during the period. Finally, UBS Group AG grew its position in Exelixis by 40.2% during the 4th quarter. UBS Group AG now owns 3,722,334 shares of the biotechnology company’s stock worth $163,150,000 after acquiring an additional 1,067,265 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance

NASDAQ:EXEL opened at $53.50 on Friday. The stock’s fifty day moving average price is $47.80 and its two-hundred day moving average price is $44.83. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $53.93. The company has a market cap of $13.45 billion, a price-to-earnings ratio of 17.77, a P/E/G ratio of 1.52 and a beta of 0.41.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm had revenue of $610.81 million for the quarter, compared to the consensus estimate of $607.51 million. During the same quarter in the prior year, the business earned $0.55 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. On average, equities analysts predict that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Stifel Nicolaus increased their price target on Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada decreased their price target on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research report on Monday, March 2nd. TD Cowen increased their price target on Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley increased their price target on Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, HC Wainwright increased their price target on Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $47.35.

Insider Activity

In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the transaction, the executive vice president owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. This represents a 8.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher J. Senner sold 34,901 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the transaction, the chief financial officer directly owned 952,317 shares in the company, valued at approximately $47,615,850. This trade represents a 3.54% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 219,170 shares of company stock worth $10,620,641. 2.60% of the stock is owned by company insiders.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.